HUMANA INC Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2023-08-18: Study NCT06066541; Company role Collaborator; Phase Not applicable; Status Completed.
- 2021-08-18: Study NCT04862858; Company role Lead sponsor; Phase Not applicable; Status Unknown.
- 2021-07-01: Study NCT05161429; Company role Collaborator; Phase Observational; Status Unknown.
- 2017-09-25: Study NCT03259373; Company role Collaborator; Phase Not applicable; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2023-08-18 | NCT06066541 Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence | Collaborator Lead: Brigham and Women's Hospital | Not applicable | Completed Results posted | Medication Adherence; Hypertension | 65,177 | 2023-12-31 |
| 2021-08-18 | NCT04862858 Educational Intervention to Increase Select Guideline-recommended Cardioprotective Medications in Patients With Diabetes | Lead sponsor | Not applicable | Unknown | Diabetes Mellitus, Type 2; Cardiovascular Diseases | 4,197 | 2022-08-16 |
| 2021-07-01 | NCT05161429 BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes | Collaborator Lead: Brigham and Women's Hospital | Observational | Unknown | Diabetes Mellitus, Type 2 | 550,000 | 2024-06-30 |
| 2017-09-25 | NCT03259373 IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation | Collaborator Lead: Harvard Pilgrim Health Care | Not applicable | Completed Results posted | Atrial Fibrillation; Stroke | 64,666 | 2021-12-31 |
| 2016-04 | NCT02697916 Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term | Collaborator Lead: Duke University | Not applicable | Completed Results posted | Atherosclerotic Cardiovascular Disease | 15,076 | 2020-06-30 |
| 2014-01 | NCT02469402 Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality | Collaborator Lead: Waldkrankenhaus Protestant Hospital, Spandau | Not applicable | Completed | Overweight | 120 | 2016-12-31 |
| 2012-06 | NCT01603329 Increasing Medication Adherence Through Physician Incentives and Messaging | Collaborator Lead: National Bureau of Economic Research, Inc. | Not applicable | Completed | Medication Adherence | 734 | 2014-03 |
| 2010-06 | NCT02037685 Improving Adherence to Statins Among Minority Populations | Collaborator Lead: University of Miami | Not applicable | Completed | Dyslipidemia | 779 | 2015-12 |
| 2010-01 | NCT01651208 Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations | Collaborator Lead: University of Miami | Not applicable | Completed Results posted | Coronary Artery Disease | 452 | 2012-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CENTENE CORP (CNC) | United States | $30.588B | -6.22 |
| Cigna Group (CI) | United States | $70.160B | 10.44 |
| MOLINA HEALTHCARE, INC. (MOH) | United States | $10.091B | -1,697.50 |
| Elevance Health, Inc. (ELV) | United States | $86.364B | 16.90 |
| Alignment Healthcare, Inc. (ALHC) | United States | $1.593B | 121.28 |
| TRUPANION, INC. (TRUP) | United States | $0.984B | |
| UNITEDHEALTH GROUP INC (UNH) | United States | $336.652B | 26.62 |